



2023

Convenors: Isabelle Boutron, Julian Higgins, Asbjørn Hróbjartsson, Matthew Page

Coordinator: Camilla Hansen



Highlight: Rollout of the revised Cochrane tool to assess risk of bias in randomized trials (RoB 2)



Research and development

- Leading the work on developing a tool for assessing risk of bias due to missing evidence (ROB-ME) – preliminary version [now available](#).
- Leading the work on developing a tool for addressing conflicts of interest in randomised trials (TACIT) – preliminary version is being pilot-tested.
- Leading the work on developing version 2 of the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool.
- Leading a [living network meta-analysis](#) of interventions for COVID-19.
- Release of a preliminary version of [ROBINS-E](#).



Best practice and guidance

- Leading quality control on the risk of bias assessments of trials in [living network meta-analysis of interventions for COVID-19](#).
- Contribute to updating SPIRIT and CONSORT reporting guidelines.



Methods implementation

- [Workshop](#) on risk of bias assessments.
- [Paper](#) in BMJ EBM on RoB2.
- Provided feedback on Cochrane's new Editorial Manager system.
- Available to support Cochrane Reviews.